A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801.

Published

Journal Article

Initial therapy of chronic graft-versus-host disease is prednisone ± a calcineurin-inhibitor, but most patients respond inadequately. In a randomized, adaptive, phase II/III, multicenter trial we studied whether prednisone/sirolimus or prednisone/sirolimus/photopheresis was more effective than prednisone/sirolimus/calcineurin-inhibitor for treating chronic graft-versus-host disease in treatment-naïve or early inadequate responders. Primary endpoints of this study were proportions of subjects alive without relapse or secondary therapy with 6-month complete or partial response in phase II, or with 2-year complete response in phase III. The prednisone/sirolimus/photopheresis arm closed prematurely because of slow accrual and the remaining two-drug versus three-drug study ended in phase II due to statistical futility with 138 evaluable subjects. The two-drug and three-drug arms did not differ in rates of 6-month complete or partial response (48.6% versus 50.0%, P=0.87), or 2-year complete response (14.7% versus 15.5%, P=0.90). Serum creatinine values >1.5 times baseline were less frequent in the calcineurin-inhibitor-free arm at 2 months (1.5% versus 11.7%, P=0.025) and 6 months (7.8% versus 24.0%, P=0.016). Higher adjusted Short Form-36 Physical Component Summary and Physical Functioning scores were seen in the two-drug arm at both 2 months (P=0.02 and P=0.04, respectively) and 6 months (P=0.007 and P=0.001, respectively). Failure-free survival and overall survival rates at 2 years were similar for patients in the the two-drug and three-drug arms (48.6% versus 46.2%, P=0.78; 81.5% versus 74%, P=0.28). Based on similar long-term outcomes, prednisone/sirolimus is a therapeutic alternative to prednisone/sirolimus/calcineurin-inhibitor for chronic graft-versus-host disease, being easier to administer and better tolerated. Clinicaltrials.gov identifier: NCT01106833.

Full Text

Duke Authors

Cited Authors

  • Carpenter, PA; Logan, BR; Lee, SJ; Weisdorf, DJ; Johnston, L; Costa, LJ; Kitko, CL; Bolaños-Meade, J; Sarantopoulos, S; Alousi, AM; Abhyankar, S; Waller, EK; Mendizabal, A; Zhu, J; O'Brien, KA; Lazaryan, A; Wu, J; Nemecek, ER; Pavletic, SZ; Cutler, CS; Horowitz, MM; Arora, M; BMT CTN.,

Published Date

  • November 2018

Published In

Volume / Issue

  • 103 / 11

Start / End Page

  • 1915 - 1924

PubMed ID

  • 29954931

Pubmed Central ID

  • 29954931

Electronic International Standard Serial Number (EISSN)

  • 1592-8721

Digital Object Identifier (DOI)

  • 10.3324/haematol.2018.195123

Language

  • eng

Conference Location

  • Italy